Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cisplatin + etoposide + paclitaxel
- Development stage
- Unknown
- Lead developer
- Michigan State University
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
A chemotherapy combination regimen consisting of cisplatin, etoposide, and paclitaxel. This three-drug combination has been studied primarily for the treatment of small cell lung cancer (SCLC), in both extensive-stage and limited-stage disease. The regimen has demonstrated high response rates (up to 90% in some studies) with manageable toxicity profiles. When combined with concurrent thoracic radiotherapy, it has shown promising survival outcomes in limited-stage SCLC.
02
Targets
TOP2A (DNA topoisomerase II)MicrotubuleDNA
Beyond the preview
Go deeper on cisplatin + etoposide + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cisplatin + etoposide + paclitaxel.